)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals (LXRX) investor relations material
Lexicon Pharmaceuticals H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary14 Sep, 2026
Strategic transformation and pipeline progress
Focus has shifted to cardiometabolic diseases, with late-stage programs for sotagliflozin in type 1 diabetes and hypertrophic cardiomyopathy (HCM) as key priorities.
Enrollment in the SONATA-HCM phase III trial exceeded targets, with over 500 patients, and top-line data expected in Q1 2027.
The STENO1 study in type 1 diabetes completed recruitment, supporting a planned FDA resubmission in Q4 2026.
Partnerships with Viatris and Novo Nordisk are advancing, with milestone payments and international approvals for heart failure indications.
Pre-launch and commercialization activities are underway, including key leadership hires and expanded medical affairs teams.
Clinical and scientific insights
Sotagliflozin targets both SGLT1 and SGLT2, offering potential benefits in HCM by improving cardiac energetics and addressing diastolic dysfunction.
SONATA-HCM is the largest trial to date for both obstructive and non-obstructive HCM, with broad inclusion criteria and pragmatic design.
The drug's safety profile in heart failure and oral, once-daily dosing position it as a potential first-line option for HCM.
Market research indicates significant unmet need and physician interest in non-obstructive HCM, where no approved therapies exist.
The trial design allows for inclusion of patients with lower ejection fractions, broadening potential applicability.
Forward-looking statements and milestones
Top-line SONATA-HCM data is expected in Q1 2027, with potential for first-in-class approval in both obstructive and non-obstructive HCM.
FDA resubmission for type 1 diabetes is planned for Q4 2026, with a potential decision in 2027.
Phase III for pilavapadin in diabetic peripheral neuropathic pain is set to begin, with additional indications under evaluation.
Novo Nordisk may initiate phase II for LX9851 in obesity, triggering further milestone payments.
The next six months are expected to bring significant clinical, regulatory, and commercial developments.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lexicon Pharmaceuticals
- Phase III HCM data for sotagliflozin expected Q1, with strong pipeline and regulatory momentum.LXRX
12th Annual Cantor Fitzgerald Global Healthcare Conference - SONATA-HCM phase III data expected Q1 2027, with T1D resubmission and pipeline advances underway.LXRXCitigroup’s Biopharma Back to School Summit 2026
- Shares registered for resale by warrant holders; no proceeds to company; focus on heart failure drugs.LXRXRegistration filing
- Q2 2026 net loss was $31.8M; SONATA-HCM Phase 3 enrollment completed, NDA resubmission Q4 2026.LXRXQ2 2026
- Advancing late-stage pipeline and global partnerships position for strong clinical and financial momentum.LXRXJefferies Global Healthcare Conference 2025
- Major clinical and partnership milestones achieved, with pivotal data and regulatory catalysts ahead.LXRXEvercore ISI 8th Annual HealthCONx Conference
- Multiple late-stage programs approach pivotal milestones, with regulatory and clinical catalysts ahead.LXRXJefferies London Healthcare Conference 2024
- LX9211 and pilavapadin advance as non-opioid therapies with imminent phase IIb data in DPNP.LXRXR&D Day 2025
- Revenue and cash rose on INPEFA sales and Viatris deal; pilavapadin advanced to Phase 3.LXRXQ4 2024
Next Lexicon Pharmaceuticals earnings date
Q3 20265 Nov, 2026
Lexicon Pharmaceuticals
Next Lexicon Pharmaceuticals earnings date
Q3 20265 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Lexicon Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of diseases with significant unmet medical needs. The company leverages its expertise in gene science to discover and develop small-molecule drugs aimed at addressing serious conditions such as heart disease, diabetes, and cancer. Lexicon's drug development approach involves targeting specific molecular pathways to create novel therapies that can alter the course of these diseases and improve patient outcomes. The company is headquartered in The Woodlands, Texas, and its shares are listed on the NASDAQ.